Alliance Resource Partners, L.P., Alliance to Participate in the 22 nd Annual Energy Infrastructure Council CEO & Investor Conference
A presentation will also be available May 21, 2025 on ARLP's website (www.arlp.com) under "Investors" and "Events & Presentations."
About Alliance Resource Partners, L.P.
ARLP is a diversified energy company that is currently the second largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is positioning itself as a reliable energy partner for the future by pursuing opportunities that support the growth and development of energy and related infrastructure.
News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission ("SEC"), are available at www.arlp.com. For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at investorrelations@arlp.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Nektar Therapeutics Stock Popped 6% on Friday
Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Do the experts think Nektar Therapeutics is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Nektar Therapeutics make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,047% vs. just 181% for the S&P — that is beating the market by 865.68%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Popped 6% on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Craig-Hallum Maintains Buy on Enphase (ENPH) Despite Clean Energy Headwinds
Enphase Energy, Inc. (NASDAQ:ENPH) is one of the best battery tech stocks to buy right now. Eric Stine, an analyst at Craig-Hallum, has kept a Buy rating on Enphase Energy, Inc. (NASDAQ:ENPH), without a price target. Stine showed continued support for the company despite ongoing challenges in the clean energy sector. While the solar industry has seen slower demand recently, some analysts still see room for growth in firms with strong technology and stable operations. A solar panel array stretched across a large open field, its glimmering panels reflecting the sun. Enphase Energy makes microinverters and energy management systems. These are used mainly in solar power setups, helping improve how energy is stored and used. The company has faced recent pressures, like weaker sales and cautious consumer spending, but it still holds a solid position in its field. Analysts believe that demand will return or that the company will adjust its costs and production to better fit market conditions. Though the stock has dropped since the end of 2022, some believe the lower price offers a chance for recovery. The analyst's decision to maintain a positive view could suggest belief in the company's ability to perform better in the future as the energy market changes. While we acknowledge the potential of ENPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Benchmark Hikes Enovix (ENVX) Price Target, Citing AI-1 Platform Strength
Enovix Corporation (NASDAQ:ENVX) is one of the best battery tech stocks to buy right now. Benchmark has raised its price target on Enovix Corporation (NASDAQ:ENVX) from $15 to $25 on July 25. The firm also kept its Buy rating on the stock. The decision to raise the target is based on how well Enovix has been performing lately. The analyst pointed to the company's recent progress and said it shows strong execution. A technician in a hardhat examining a subsea battery system. Another reason for the higher price target is the AI-1 platform. According to the analyst, this platform is very important for Enovix's future. It is seen as a big step forward for the company. The AI-1 platform could help Enovix grow and stay competitive in the battery technology space. Because of this, the analyst believes the company has more value than before. Enovix has been working hard on new battery technology. The AI-1 platform shows that the company is serious about leading in this space. Benchmark seems confident that Enovix is moving in the right direction. With better execution and promising new products, the stock could continue to go up. In summary, the raised price target reflects stronger performance and the growing importance of the company's new technology. Benchmark remains positive about Enovix's future and continues to recommend buying the stock. Enovix is a battery technology company developing advanced lithium-ion batteries with silicon-anode architecture. Its innovative designs aim to deliver higher energy density, improved safety, and better performance for applications in consumer electronics, wearables, and future electric vehicles. While we acknowledge the potential of ENVX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 12 Best Performing AI Stocks So Far in 2025 and 10 Best Military Tech Stocks to Buy Now Disclosure: None.
